{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=INO-9012", "query": { "intervention": "INO-9012" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 15, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=INO-9012&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T08:35:17.687Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02172911", "title": "A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "INO-3112", "type": "BIOLOGICAL" }, { "name": "CELLECTRA™-5P", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2014-06-06", "completion_date": "2017-09-07", "has_results": true, "last_update_posted_date": "2021-02-21", "last_synced_at": "2026-09-03T08:35:17.687Z", "location_count": 3, "location_summary": "Chicago, Illinois • Ann Arbor, Michigan • New York, New York", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02172911" }, { "nct_id": "NCT02514213", "title": "Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "2mg INO-5150 and electroporation device CELLECTRA®-5P", "type": "BIOLOGICAL" }, { "name": "8.5mg INO-5150 and electroporation device CELLECTRA®-5P", "type": "BIOLOGICAL" }, { "name": "2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P", "type": "BIOLOGICAL" }, { "name": "8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P", "type": "BIOLOGICAL" }, { "name": "Electroporation using CELLECTRA®-5P", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "MALE", "summary": "18 Years to 90 Years · Male only" }, "enrollment_count": 62, "start_date": "2015-07", "completion_date": "2017-12-12", "has_results": false, "last_update_posted_date": "2017-12-26", "last_synced_at": "2026-09-03T08:35:17.687Z", "location_count": 10, "location_summary": "Baltimore, Maryland • Detroit, Michigan • Omaha, Nebraska + 7 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02514213" }, { "nct_id": "NCT02241369", "title": "Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Aerodigestive Precancerous Lesions and Malignancies" ], "interventions": [ { "name": "INO-3106, INO-9012", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2014-05", "completion_date": "2018-09", "has_results": false, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-09-03T08:35:17.687Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02241369" }, { "nct_id": "NCT03606213", "title": "Therapeutic Vaccination in Treated HIV Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "PENNVAX-GP", "type": "BIOLOGICAL" }, { "name": "INO-6145", "type": "BIOLOGICAL" }, { "name": "INO-9012", "type": "BIOLOGICAL" }, { "name": "CELLECTRA® 2000", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Steven Deeks", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 56, "start_date": "2018-08-01", "completion_date": "2021-05-17", "has_results": true, "last_update_posted_date": "2023-05-31", "last_synced_at": "2026-09-03T08:35:17.687Z", "location_count": 2, "location_summary": "Los Angeles, California • San Francisco, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03606213" }, { "nct_id": "NCT02464670", "title": "Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ebola Vaccine" ], "interventions": [ { "name": "INO-4201", "type": "BIOLOGICAL" }, { "name": "INO-4202", "type": "BIOLOGICAL" }, { "name": "INO-4212", "type": "BIOLOGICAL" }, { "name": "INO-4212 + INO-9012", "type": "BIOLOGICAL" }, { "name": "INO-4201 + INO-9012", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 240, "start_date": "2015-05", "completion_date": "2018-05-24", "has_results": false, "last_update_posted_date": "2019-06-28", "last_synced_at": "2026-09-03T08:35:17.687Z", "location_count": 3, "location_summary": "Miami, Florida • Kansas City, Missouri • Philadelphia, Pennsylvania", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02464670" }, { "nct_id": "NCT04251117", "title": "GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HCC" ], "interventions": [ { "name": "GNOS-PV02", "type": "BIOLOGICAL" }, { "name": "INO-9012", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "CELLECTRA®2000 EP Device", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE" ], "sponsor": "Geneos Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2020-03-01", "completion_date": "2028-11-29", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-09-03T08:35:17.687Z", "location_count": 2, "location_summary": "Baltimore, Maryland • New York, New York", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04251117" }, { "nct_id": "NCT07722741", "title": "Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HCC" ], "interventions": [ { "name": "GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation", "type": "BIOLOGICAL" }, { "name": "Electroporation Device", "type": "DEVICE" }, { "name": "INO-9012", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Geneos Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2026-09", "completion_date": "2032-06", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-03T08:35:17.687Z", "location_count": 7, "location_summary": "Atlanta, Georgia • New Orleans, Louisiana • Baltimore, Maryland + 4 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07722741" }, { "nct_id": "NCT03502785", "title": "INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "INO-5401", "type": "BIOLOGICAL" }, { "name": "INO-9012", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "CELLECTRA® 2000", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2018-07-24", "completion_date": "2025-05-09", "has_results": true, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-03T08:35:17.687Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Tampa, Florida • Baltimore, Maryland + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03502785" }, { "nct_id": "NCT02960594", "title": "hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Lung Cancer", "Pancreatic Cancer", "Head and Neck Cancer", "Ovarian Cancer", "ColoRectal Cancer", "Gastric Cancer", "Esophageal Cancer", "HepatoCellular Carcinoma" ], "interventions": [ { "name": "INO-1400", "type": "BIOLOGICAL" }, { "name": "INO-9012", "type": "BIOLOGICAL" }, { "name": "INO-1401", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 93, "start_date": "2014-12", "completion_date": "2018-11-09", "has_results": false, "last_update_posted_date": "2018-11-19", "last_synced_at": "2026-09-03T08:35:17.687Z", "location_count": 6, "location_summary": "Detroit, Michigan • Rochester, Minnesota • Chapel Hill, North Carolina + 2 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02960594" }, { "nct_id": "NCT04015700", "title": "Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics", "type": "BIOLOGICAL" }, { "name": "CELLECTRA®2000 EP Device supplied by Geneos Therapeutics", "type": "DEVICE" }, { "name": "Plasmid encoded IL-12", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2020-07-14", "completion_date": "2027-09-03", "has_results": true, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-09-03T08:35:17.687Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04015700" } ] }